Stuart J. Connolly
Stuart J. Connolly
Professor in the Faculty of Health Sciences. McMaster University, Hamilton, Ontario, Canada
Dr Connolly is a leading scientist at Population Health Research Institute.
Dr Connolly holds a M.D. from McGill University in Montreal, Canada. He received his specialist training in cardiology at the University of Toronto in Canada and at Stanford University in the United States.
Dr Connolly is a practicing clinical cardiologist and Electrophysiologist. He is division director for cardiology at McMaster University.
His main research interest is evaluation of treatments for management of heart rhythm disorders. He has designed and implemented > 25 randomised clinical trials. Among the studies of which he was the principal investigator are the Canadian Atrial Fibrillation Anticoagulation (CAFA) Study, The Canadian Amiodarone Myocardial Infarction Arrhythmiai Trial (CAMIAT), the Canadian Implantable Defibrillator Study (CIDS), The Canadian Trial of Physiologic Pacing (CTOPP) and two Vasovagal Pacemaker Studies (VPS –1 and VPS-2). Dr. Connolly is principal investigator of the Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events
Dr Connolly has published more than 180 scientific articles over his career and is currently a member of the editorial boards for Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology.
Professor in the Faculty of Health Sciences. McMaster University, Hamilton, Ontario, Canada
Dr Connolly is a leading scientist at Population Health Research Institute.Dr Connolly holds a M.D. from McGill University in Montreal, Canada. He received his specialist training in cardiology at the University of Toronto in Canada and at Stanford University in the United States.
Dr Connolly is a practicing clinical cardiologist and Electrophysiologist. He is division director for cardiology at McMaster University.
His main research interest is evaluation of treatments for management of heart rhythm disorders. He has designed and implemented > 25 randomised clinical trials. Among the studies of which he was the principal investigator are the Canadian Atrial Fibrillation Anticoagulation (CAFA) Study, The Canadian Amiodarone Myocardial Infarction Arrhythmiai Trial (CAMIAT), the Canadian Implantable Defibrillator Study (CIDS), The Canadian Trial of Physiologic Pacing (CTOPP) and two Vasovagal Pacemaker Studies (VPS –1 and VPS-2). Dr. Connolly is principal investigator of the Atrial Fibrillation Clopidogrel Trial With Irbesartan For Prevention Of Vascular Events
Dr Connolly has published more than 180 scientific articles over his career and is currently a member of the editorial boards for Heart, the American Heart Journal and the Journal of Pacing and Electrophysiology.
Latest videos
The True Cost of Atrial Fibrillation
Latest Congress Announcement
ESC Congress 2011
This year, ESC Congress goes to Paris. The event is the year’s “Rendez-vous” for everybody involved in Cardiovascular Medicine, from clinical practitioners to basic scientists, epidemiologists, nurses, technicians, health care industry, opinion leaders and policy makers from around the world.
Paris, France.
Paris, France.